Home LiteratureArticle Details
PMID: 11377445 Published · ppublish English Journal Article Review

Physiological approaches to neuroprotection. boosting of protective autoimmunity.

Survey of ophthalmology ·Vol. 45 Suppl 3 ·2001-05-00 ·Pages S256-60; discussion S273-6

Schwartz M

Abstract

In glaucoma, as in other degenerative diseases of the central nervous system (CNS), there are some neurons which, although susceptible to degeneration, are amenable to neuroprotection. Until very recently, attempts to attenuate the spread of damage after CNS trauma or in neurodegenerative diseases did not include recruitment of the immune system, because it was assumed that in the CNS any immune activity, particularly autoimmune activity, would be harmful. Using the injured optic nerve of the rat as a model, we recently showed, however, that this 'secondary degeneration' can be slowed down by a well-controlled adaptive immune response, which is mediated by T cells against CNS self-antigens, such as myelin basic protein (MBP), and can be achieved either by passive transfer of MBP-activated T cells or by active immunization with MBP. Accordingly, we suggested that autoimmune T cells can be neuroprotective. We further showed that the neuroprotective autoimmunity is a physiological response to the injury, perhaps insufficient in its natural state, but amenable to boosting. The neuroprotective activity of these T cells probably depends on their reactivation by their specific antigen after they are targeted to the injured nerve. As nerve degeneration is initiated and sustained by many factors, it would probably best be counteracted by a comprehensive type of therapy rather than treatment that addresses only some aspects of nerve damage. T cell therapy, being physiological rather than pharmaceutical in nature, may provide a global answer. However, since the neuroprotective immune response is directed against the self, it must be rigorously regulated to avoid inducing an autoimmune disease. We showed that the synthetic copolymer Cop-1 can passively or actively evoke T cell-mediated neuroprotection, probably by cross-reacting with MBP. Safe synthetic peptides that resemble self-antigens and are cross-activated by CNS-associated self antigens may be a useful starting point for the development of anti-self immunity for neuroprotective purposes.

MeSH Terms
Autoimmunity/physiology Cell Survival/physiology Glaucoma/immunology,therapy Humans Immunotherapy, Adoptive Optic Nerve Diseases/immunology,therapy T-Lymphocytes/immunology
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Schwartz M
Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel. [email protected]
Article Info
Journal
Survey of ophthalmology
Abbr.
Surv Ophthalmol
ISSN
0039-6257
Published
2001-05-00
Pages
S256-60; discussion S273-6
Language
English
Region
United States
NLM ID
0404551
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]